Inflation and rising interest rates: The global inflation risk stemming from geopolitical conflicts and domestic CPI data, coupled with central bank rate hike probabilities (e.g., BoJ), directly increases the cost of capital and operating expenses for Aclarion. As an early-stage commercial healthcare technology company, Aclarion relies on external financing for its development and market penetration, making it highly sensitive to changes in borrowing costs.

Healthcare spending trends and economic uncertainty: Broader economic conditions, influenced by global conflicts, can impact overall healthcare spending. While Aclarion targets chronic low back pain diagnostics, which may be less elective, economic uncertainty could still lead to slower adoption rates by healthcare providers or delays in securing broader reimbursement, thus affecting the company's revenue growth.

Regulatory and reimbursement landscape in healthcare: A critical factor for Aclarion's commercial success is the evolving regulatory and reimbursement environment. News items repeatedly highlight the company's efforts in pursuing reimbursement coverage from insurers. Favorable or unfavorable shifts in healthcare policy and payer acceptance directly influence the scalability and market penetration of Aclarion's Nociscan platform.